GRI Stock Analysis: Buy, Sell, or Hold?
GRI - GRI Bio, Inc. Common Stock
$1.96
0.10 (5.38%)
▲
5d:
-9.68%
30d:
-4.85%
90d:
-19.34%
HOLD
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When GRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GRI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GRI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GRI is currently trading at $1.96, which is considered oversold relative to its 30-day fair value range of $2.04 to $2.26.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: GRI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+1029.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: GRI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+1029.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.04 -
$2.26
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 1029.0% below Wall St target ($21.00)
- CAUTION: Recommendation downgraded due to -9.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.04 -
$2.26
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.97
Resistance Level
$2.31
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.73
Wall Street Target
$21.00
(+1029.0%)
Share & Embed Analysis
Last updated: June 24, 2026 12:24 PM ET
Data refreshes hourly during market hours. Next update: 1:24 PM
Data refreshes hourly during market hours. Next update: 1:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 59 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 65 BUY |
